Grifols (GIFLF) Short-term Investments (2009 - 2025)
Grifols' (GIFLF) quarterly Short-term Investments came in at $201.4 million in Q4 2025, down 20.82% on a YoY basis from $254.3 million in Q4 2024, and down 20.82% quarter-over-quarter from $254.3 million in Q4 2024.
Analysis
Grifols (GIFLF) Short-term Investments (2009 - 2025) Analysis & Trends
Grifols (GIFLF) has reported Short-term Investments for 17 consecutive years, with $201.4 million the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, Short-term Investments fell 20.82% year-over-year to $201.4 million; the trailing twelve-month figure through Dec 2025 stood at $201.4 million (down 20.82% YoY), and the FY2025 full-year result was $195.5 million, down 23.15% from the prior year.
- Short-term Investments declined to $201.4 million in Q4 2025 per GIFLF's latest filing, from $254.3 million in the prior quarter.
- Across five years, Short-term Investments topped out at $2.3 billion in Q4 2021 and bottomed at -$100.1 million in Q4 2023.
- Historically, Short-term Investments has averaged $628.2 million across 5 years, with a median of $254.3 million in 2024.
- The sharpest annual moves came in 2021 and 2023: Short-term Investments surged 7238.35% in 2021, then sank 121.41% in 2023.
- Over 5 years, Short-term Investments stood at $2.3 billion in 2021, then slumped by 79.84% to $467.3 million in 2022, then tumbled by 121.41% to -$100.1 million in 2023, then soared by 354.17% to $254.3 million in 2024, then dropped by 20.82% to $201.4 million in 2025.
- According to Business Quant data, Short-term Investments over the past three periods registered $201.4 million, $254.3 million, and -$100.1 million for Q4 2025, Q4 2024, and Q4 2023 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 203.97 Bn | 189.99 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 178.74 Bn | 175.56 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.73 Bn | 122.88 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 80.42 Bn | 72.42 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.40 Bn | 55.21 Bn | 1.37 Bn |
| 6 | Moderna | 57.65 Bn | 52.52 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.37 Bn | 30.07 Bn | 992.69 Mn |
| 8 | Biogen | 32.15 Bn | 30.86 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.58 Bn | 29.58 Bn | 1.16 Mn |
| 10 | Grifols | 7.54 Bn | 9.09 Bn | 3.33 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 201.38 Mn |
| Dec 31, 2024 | 254.33 Mn |
| Dec 31, 2023 | -100.06 Mn |
| Dec 31, 2022 | 467.32 Mn |
| Dec 31, 2021 | 2.32 Bn |
| Dec 31, 2020 | -32.48 Mn |
| Sep 30, 2020 | 14.35 Mn |
| Mar 31, 2020 | 14.39 Mn |
| Dec 31, 2019 | -21.53 Mn |
| Sep 30, 2019 | 3.08 Mn |
| Mar 31, 2019 | 202.58 Mn |
| Dec 31, 2018 | 122.81 Mn |
| Sep 30, 2018 | 59.78 Mn |
| Jun 30, 2018 | 45.28 Mn |
| Mar 31, 2018 | 12.92 Mn |
| Dec 31, 2017 | 12.64 Mn |
| Jun 30, 2017 | 22.56 Mn |
| Dec 31, 2016 | 2.79 Mn |
| Sep 30, 2016 | 1.99 Mn |
| Jun 30, 2016 | 9.07 Mn |